ARS Pharmaceuticals, Inc (SPRY) — Cash Flow-to-Debt Ratio
ARS Pharmaceuticals, Inc (SPRY) has a Cash Flow-to-Debt Ratio of -0.20x as of December 2025, meaning its operating cash flow of $-43.48 Million could theoretically repay 0% of its total liabilities ($213.39 Million) in one year. See ARS Pharmaceuticals, Inc (SPRY) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ARS Pharmaceuticals, Inc Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for ARS Pharmaceuticals, Inc across 8 annual periods. Also explore SPRY net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for ARS Pharmaceuticals, Inc (2018–2025)
Year-by-year debt coverage analysis for ARS Pharmaceuticals, Inc. For market capitalisation and broader financial context, see ARS Pharmaceuticals, Inc (SPRY) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.80x | $-170.87 Million | $213.39 Million | ▼ -657.7% |
| 2024 | 0.14x | $13.55 Million | $94.36 Million | ▲ +100.6% |
| 2023 | -24.41x | $-59.27 Million | $2.43 Million | ▼ -420.7% |
| 2022 | -4.69x | $-40.08 Million | $8.55 Million | ▼ -2375.1% |
| 2021 | -0.19x | $-17.56 Million | $92.72 Million | ▼ -184.5% |
| 2020 | 0.22x | $9.07 Million | $40.46 Million | ▲ +125.2% |
| 2019 | -0.89x | $-18.90 Million | $21.25 Million | ▲ +50.7% |
| 2018 | -1.80x | $-16.88 Million | $9.35 Million | — |